NIP
DNTH icon

Nicholas Investment Partners’s Dianthus Therapeutics DNTH Stock Holding History

Nicholas Investment Partners’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.2M Buy
186,769
+135,519
+264% +$11.8M 1.03% 24
2026
Q1 		$4.3M Buy
+51,250
New +$2.97M 0.31% 110
2018
Q4 		– Sell
-1,823
Closed -$350K – 224
2018
Q3 		$350K Buy
1,823
+525
+40% +$110K 0.03% 214
2018
Q2 		$280K Buy
+1,298
New +$293K 0.02% 221

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Nicholas Investment Partners's DNTH Position: Q2 2026 in Review

Nicholas Investment Partners increased its Dianthus Therapeutics (DNTH) stake by 264% in Q2 2026, buying an estimated $11.8M and bringing the position to 186,769 shares worth $18.2M. The position accounts for 1.03% of the portfolio, ranked #24.

Nicholas Investment Partners first reported a position in DNTH in Q2 2018 and has held it in 4 quarters since. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Nicholas Investment Partners held 186,769 shares of Dianthus Therapeutics worth $18.2M as of Q2 2026.
  • Nicholas Investment Partners bought 135,519 Dianthus Therapeutics shares in Q2 2026, an estimated $11.8M.
  • Dianthus Therapeutics made up 1.03% of Nicholas Investment Partners's portfolio in Q2 2026, its #24 holding.
  • Nicholas Investment Partners first reported a position in Dianthus Therapeutics in Q2 2018 and has held it in 4 quarters since.
  • 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Nicholas Investment Partners's 13F filing for Q2 2026, filed 14 Aug 2026.